Efficacy and safety of eribulin in various subtypes of breast cancer: data from real clinical practice in Russia

Л В Манзюк ,Liudmila V Vorotilina ,Н О Попова ,Л В Болотина ,Я В Светицкая ,Mikhail V Shaidorov ,Irina S Mitashok ,Vera Gorbunova ,Garnik S Tumanian ,А Ю Повышев ,Е В Карабина ,И В Евстигнеева ,Т А Снежко ,Т Ю Семиглазова ,И И Андреяшкина ,Н Ю Саманева ,Ю А Мишина ,Elena A Kalabanova ,Tatiana Andreeva ,А И Хасанова ,V Е Goldberg ,С В Лимарева ,Д М Пономаренко ,Н М Тихановская ,Anna E Storozhakova ,Sufia Safina ,Guzel Mukhametshina ,А А Тетерич ,Irina L Popova ,Larisa A Zhiliaeva ,Е А Гайсина ,А Е Козяков ,В А Чубенко ,Л Ю Владимирова ,Е И Коваленко ,Е П Прокофьева ,Natalya A Abramova ,Inna V Iudina ,Liudmila A Gil'mutdinova

doi:10.18027/2224-5057-2017-3-46-56

Efficacy and safety of eribulin in various subtypes of breast cancer: data from real clinical practice in Russia

Л В Манзюк , Liudmila V Vorotilina + Show 37 more

https://doi.org/10.18027/2224-5057-2017-3-46-56

Copy DOI

Journal: Malignant tumours

Publication Date: Jan 1, 2017

Affiliation: ФГБУ «Ростовский научно-исследовательский онкологический институт»

#Use Of Eribulin #Real Clinical Practice In Russia + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

The article presents a pooled experience of the use of eribulin in the real clinical practice of treatment of metastatic breast cancer in Russian oncological institutions. The effectiveness of the drug in monotherapy with HER2‑negative breast cancer was analyzed, groups of patients with most effective use of eribulin were identified depending on the localization of metastases, the most effective lines of therapy. The effectiveness of the drug in combination with trastuzumab in HER2‑positive breast cancer is described, as well as toxic reactions.

Full Text